VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
Open accessThe DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.
Abstract
VEGF-A drives T cell exhaustion via TOX-dependent transcriptional programming in microsatellite stable colorectal cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [60]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 1×
“INTRODUCTION Tumor antigen–specific T cells within the tumor microenvironment are exhausted, and their antitumor functions are substantially impaired (1, 2).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Cited by
Items 101–200 of 250
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 33
“In microsatellite stable colorectal cancer, vascular endothelial growth factor-A (VEGF-A) induces TOX expression, which increases the levels of the coinhibitory immune checkpoint molecules PD-1, TIM3, LAG3 and TIGIT (see below) in CD8 T cells and thereby drives T-cell exhaustion.(37) Whether this occurs in liver cance…”
BackgroundHuang, S., Liang, C., Zhao, Y., Deng, T., Tan, J., Lu, Y., Liu, S., Li, Y., & Chen, S. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13545 · Cited by 24
Resistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 27
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 27
“Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, et al. TOX transcriptionally and epigenet‑ ically programs CD8(+) T cell exhaustion.”
MethodInfluentialSelf-citationXu, Q., & Shao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487610 · Cited by 27
Targeting tumor-associated macrophages for cancer immunotherapy
Cao, X., Lai, S. W. T., Chen, S., Wang, S., & Feng, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.02.002 · Cited by 27
Qi, Y., Song, Y., Cai, M., Li, J., Yu, Z., Li, Y., Huang, J., Jiang, Y., Peng, C., Jiang, B., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17678 · Cited by 22
Han, J. W., & Jang, J. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411799 · Cited by 25
Self-citationDing, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.052 · Cited by 24
Shi, H., Tian, H., Zhu, T., Liao, Q., Liu, C. X., Yuan, P., Li, Y., Yang, J., Zong, C., Jia, S., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00683-y · Cited by 24
“On the other hand, previous studies have demonstrated that increased VEGF secretion decreases T cell effector function and traf fi cking to tumors 41 .”
Han, S., Cui, L., Wang, B., Ruan, Y., Shi, M., Hong, C. S., Guan, X., Chen, Z., Li, Y., Liao, Y., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1194 · Cited by 22
“VEGF-A is commonly overexpressed in colorectal cancer, in which it not only drives aberrant angiogenesis but also stimulates the expression of the transcription factor TOX in T cells, driving T-cell exhaustion (6).”
Wei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
Chen, J., Zhang, H., Zhou, L., Hu, Y., Li, M., He, Y., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584367 · Cited by 21
“VEGF-a can also induce the expression of thymocyte selection-associated high mobility group box (TOX) protein in T cells, thereby driving T cell depletion (40).”
BackgroundUnveiling the tumor microenvironment in colorectal cancer therapeutic resistance
Han, J., Liang, W., & Li, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1753180 · Cited by 21
“…of immune checkpoint blockade (ICB) resistance in microsatellite-stable (MSS) CRC. VEGF-A–driven induction of TOX enforces a transcriptional exhaustion program in T cells, limiting PD-1 blockade efficacy; dual inhibition of VEGF-A and PD-1 partially restores T-cell activity (Kim et al., 2019).”
Self-citationYang, B., Deng, B., Jiao, X., Qin, B., Lu, Y. C., Zhang, W., Guo, Y., Chen, S., Li, D., Li, B., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00718-0 · Cited by 18
“VEGF-A induced the expression of the tran - scription factor TOX in T cells to drive the exhaustion specific transcription program in CD8 + T cells [27].”
Jiang, N., Zhong, B., Huang, J., Li, W.-C., Zhang, S., Zhu, X., Ni, C., & Shen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205636 · Cited by 18
The TOX subfamily: all-round players in the immune system
Han, J., Wan, M., Ma, Z., & He, P. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac037 · Cited by 18
Self-citationSecretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
Supper, V. M., Donner, H., Birocchi, F., Bratt, A., Escobar, G., Kann, M. C., Park, S., Martin, G., Korell, F., Takei, H., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0876 · Cited by 17
Self-citationShi, Y., Li, Y., Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Lv, C., Han, S., Yu, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108968 · Cited by 17
Esfahani, A. T., Mohammadpour, S., Jalali, P., Yaghoobi, A., Karimpour, R., Torkamani, S. S., Pardakhtchi, A., Salehi, Z., & Mojarad, E. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-61000-x · Cited by 19
“The disorganized vascular network within tumors significantly inhibits the infiltration of CD8 + T cells into the tumor microenvironment, thereby compromising their efficacy 70,71 .”
BackgroundLiu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025) · Journal of Cancer · doi:10.7150/jca.108163 · Cited by 18
“T cell exhaustion could be recovered after knocking down TOX, and the combination with anti-VEGF-A treatment could improve the response to PD-1 blockade therapy [55].”
Fang, X., Zhong, C., Weng, S., Hu, H., Wang, J., Xiao, Q., Wang, J., Sun, L., Xu, D., Liao, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11139-z · Cited by 16
“Results of another study with MSS mCRC patients suggested that VEGF inhibitors can upregulate immune checkpoint responses involving the thymocyte selection-associated high mobility group box protein (TOX) transcription factor, which can mediate CD8 + T-cell exhaustion [30].”
ResultYang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y., & Shen, Z. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104204 · Cited by 17
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 17
Lü, Z., Yang, S., Luo, X., Shi, Y., Lee, J.-S., Deva, S., Liu, T., Chao, Y., Zhang, Y., Huang, R., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01308-7 · Cited by 17
Chen, Z., Zhang, M., Liu, Y., Chen, Z., Wang, L., Wang, W., Wang, J., He, M., Shi, B., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03926-w · Cited by 17
Unlocking new horizons in oncology: ivonescimab’s dual-target approach to anti-VEGF/PD-1(L1) therapy
Shi, F., Yang, L., Gao, Y., Hou, Y., Lv, Q., Cao, F., Chen, X., Zhang, J., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599181 · Cited by 19
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 18
Yang, W., Guo, Z., Ju, H., Lu, Y., Fei, Y., Yin, Y., Ren, G., Yan, M., Han, C., & Hu, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011474 · Cited by 15
Rakké, Y. S., Carrascosa, L. C., van Beek, A. A., de Ruiter, V., van Gemerden, R. S., Doukas, M., Doornebosch, P. G., Vermaas, M., ter Borg, S., van der Harst, E., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.09.007 · Cited by 17
“2352-345X https://doi.org/10.1016/j.jcmgh.2022.09.007 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 Ccommon cancer worldwide in women and men, respectively.1 In 2020, 1.9 million newly diagnosed pa…”
BackgroundInfluentialHeterogeneity of the tumor immune microenvironment and clinical interventions
Jin, Z., Zhou, Q., Cheng, J., Jia, Q., & Zhu, B. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1015-9 · Cited by 15
Zhang, X., Ye, X., & Jin, H. (2025) · Antioxidants · doi:10.3390/antiox14060726 · Cited by 19
“…adhesion molecules (e.g., ICAM-1, VCAM-1) [152]; (3) VEGF-A induces T cell exhaustion in MSS colorectal cancer by upregulating TOX expression [153]; and (4) enhanced recruitment of Tregs and MDSCs, coupled with M2 polarization of TAMs, further exacerbating the immunosuppressive milieu [154].”
Eso, Y., Taura, K., & Seno, H. (2021) · Hepatology Research · doi:10.1111/hepr.13712 · Cited by 14
Liu, X., Sun, P., Bao, X., Cao, Y., Wang, L., & Wang, Q. (2024) · Medicine · doi:10.1097/md.0000000000038052 · Cited by 18
“[78] VEGFA has been shown to regulate the generation of endothelial cells and improve microcirculation in individuals with insomnia, significantly improving sleep disorders. study of meta-analysis [79] has shown that patients with obstructive sleep apnea have significantly higher concentrations of…”
BackgroundMeng, L., Li, H., Ji, Y., Yu, P., Wang, Z., Cao, L. K., Shi, B., Shao, Y., Jin, Y., Gao, Y., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03857-5 · Cited by 14
“Complementary studies further delineate the VEGF/VEGFR axis's capacity to attenuate dendritic cell functionality and differentiation, simultaneously fostering the proliferation of myeloid-derived suppressor cells (MDSCs) [33].”
BackgroundLiu, N., Shan, F., & Ma, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108017 · Cited by 15
Ruan, L., Zhang, S., Chen, X., Liang, W., & Xie, Q. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153956 · Cited by 14
Keystone pathobionts associated with colorectal cancer promote oncogenic reprograming
Jones, J. P., Shi, Q., Nath, R. R., & Brito, I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297897 · Cited by 14
Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. B. (2023) · Cancer · doi:10.1002/cncr.34683 · Cited by 14
Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy
Nasti, T. H., & Eberhardt, C. S. (2021) · Vaccines · doi:10.3390/vaccines9121396 · Cited by 12
Yang, A., Zhou, M., Gao, Y., & Zhang, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114843 · Cited by 12
Li, W., Li, G., Luo, C.-S., Yu, Q., & Cui, M. (2025) · Cancer Management and Research · doi:10.2147/cmar.s537930 · Cited by 11
“112 VEGF also induces exhaustion of CD8 + CTLs, 113 and blockade of VEGF synergistically modulates CD8 + T-cell immune activity in tumors and potentiates their capacity to produce cytokines.”
A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 12
“This transcriptional reprogramming enforces a stable exhausted phenotype, contributing to immune evasion and resistance to PD-1 blockade (144).”
Zhang, Y., & Qu, H. (2020) · Medicine · doi:10.1097/md.0000000000021883 · Cited by 11
“Furthermore, angiogenesis plays an important role in the growth, invasion and metastasis of cancer cells.([20]) Simonetti et al found that the expression of VEGF in tumor tissue was higher than that in normal tissue, suggesting that VEGF can promote tumor microvascular formation and play an important role in the occur…”
BackgroundWu, S., Wei, Y., Qiu, Y., Ai, K., Chen, M., Wang, H., Zhang, H., Cen, Q., Liao, P., Ding, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05907-z · Cited by 15
“VEGF signaling via VEGFR2 upregulates inhibitory receptors on T cells, impairing effector functions and promoting exhaustion [18, 24].”
InfluentialZhang, Y., Yuan, Z., Jin, Y., Zhang, W., & Yuan, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122058 · Cited by 10
“In most malignant tumors, continuous angiogenesis is regarded as an important tumor marker [5,6].”
BackgroundChu, X., Bao, H., Lin, Y.-J., Chen, R., Zhang, Y., Huang, T., He, J., Huangfu, S., Pan, Y., & Ding, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965492 · Cited by 11
Tang, Q., Wu, D., Huang, H., Fang, H., Wu, Y., Liu, F., & Li, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1093194 · Cited by 9
VEGF-A in COVID-19: a systematic review and meta-analytical approach to its prognostic value
Bahreiny, S. S., Bastani, M., Keyvani, H., Fard, R. M., Aghaei, M., Mansouri, Z., Karamali, N., Sakhavarz, T., Amraei, M., & Harooni, E. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01583-5 · Cited by 10
“Studies have shown elevated VEGF-A signaling is associated with T-cell exhaustion and dysfunction [64, 65].”
Herr, F. L., Antons, M. J., Blume, L. V., Hirner-Eppeneder, H., Kloiber-Langhorst, S., Cimic, A., Stueckl, J., Tardy, I., Burkard, T., Ricke, J., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326675 · Cited by 10
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
Self-citationMcCormick, A. L., Anderson, T. S., Daugherity, E. A., Okpalanwaka, I. F., Smith, S. L., Appiah, D., & Lowe, D. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241949 · Cited by 11
The prognostic value and immunological role of angiogenesis-related patterns in colon adenocarcinoma
Sun, W., Xu, Y., Zhao, B., Zhao, M., Chen, J., Chu, Y., & Peng, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1003440 · Cited by 11
“VEGFA induces T cell depletion in anti-PD-1resistant microsatellite stable CRC patients (37).”
BackgroundSung, P. S., Cho, S. W., Lee, J., Yang, H., Jang, J. W., Bae, S. H., Choi, J. Y., & Yoon, S. K. (2020) · Journal of Liver Cancer · doi:10.17998/jlc.20.2.128 · Cited by 9
“Moreover, recent reports have demonstrated that the expression of PD-1 and other inhibitory checkpoints is upregulated by VEGF-A secreted by cancer and stromal cells and that immune regulatory function is disrupted when VEGF receptor signaling is targeted with VEGF receptor inhibitors.(23,24) These studies suggest tha…”
BackgroundSelf-citationTissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma
Han, J. W., & Yoon, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010232 · Cited by 9
“In addition, intratumoral Treg cells can produce VEGF, which is associated with tumor angiogenesis [55] and TOX-mediated T cell exhaustion [79] in other cancers.”
BackgroundSelf-citationMastrogiovanni, M., Donnadieu, E., Pathak, R., & Bartolo, V. D. (2024) · Biology · doi:10.3390/biology13110860 · Cited by 10
Wu, J., Bai, X., Yu, G., Zhang, Q., Tian, X., & Wang, Y. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05854-8 · Cited by 8
“…explanations were: (1) as men - tioned above, TACE, ICIs, and apatinib, either two of them showed synergistic anti-tumor effects (Chang et al. 2019; Kim et al. 2019 ; Liu J, Xu, et al. 2020), which resulted in a better treatment efficacy compared with TACE combined with apatinib; (2) the sample…”
BackgroundHuffman, B. M., Rahma, O. E., Tyan, K., Li, Y. Y., Giobbie‐Hurder, A., Schlechter, B. L., Bockorny, B., Manos, M. P., Cherniack, A. D., Bagińska, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1027 · Cited by 9
Targeting Angiogenesis for Advanced Hepatocellular Carcinoma
Eso, Y. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5923-20 · Cited by 8
“recently reported that VEGF-A drives TOX-dependent T cell exhaustion; therefore, the combined blockade of PD-1/PD-L1 and VEGF pathways could effectively restore the antitumor function of T cells (14).”
BackgroundMontecchi, T., Nannini, G., Tommaso, D. D., Cassioli, C., Coppola, F., Ringressi, M. N., Carraro, F., Naldini, A., Taddei, A., Marotta, G., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03614-0 · Cited by 7
“Consistent with this notion, the simultaneous blockade of PD-1 and VEGF-A in these patients restores antitumor function of T cells.(40) HIF-1α inhibition has also been shown to”
BackgroundResultClick Chemistry-Assisted Rejuvenation of Aging T Cells Sensitizes Aged Mice to Tumor Immunotherapy
Bai, X., Ma, J., Zhang, C., Chen, Z., He, J., Cheng, S., & Zhang, X. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05312 · Cited by 9
Robillard, L., Liao, M., Nguyen, M., Harding, T. C., Simmons, A. D., & Dusek, R. L. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000427 · Cited by 9
Beiter, E. R., Patel, S. R., & Chen, C. T. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01044 · Cited by 7
Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies
Huang, K., & Chen, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073064 · Cited by 6
Yang, P., Luo, H., Zhao, L., Xiong, F., & Tang, C. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-394 · Cited by 6
“The combined blockade of PD-1 and VEGFR in mouse tumor models induces strong synergistic antitumor responses, such as inhibition of VEGF-A expression and thus reducing T cell exhaustion in tumors (16,22).”
Zhang, B., Liu, H., Shi, C., Gao, Z., Zhong, R., Gu, A., Chu, T., Wang, H., Xiong, L., Zhang, W., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12479-0 · Cited by 6
“In addition, VEGF-A induces the thymocyte selection-associated high mobility group box protein (TOX)-mediated exhaustion of CD8 + T cells via transcriptional reprogramming [9].”
BackgroundHuang, S., Chen, Z., Zhong, S., Zhang, Y., Zeng, C., Zheng, X., Li, Y., & Chen, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177163 · Cited by 6
Singh, B., Kaur, P., & Maroules, M. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709621992207 · Cited by 6
Eso, Y., & Seno, H. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.04.004 · Cited by 6
Kim, K., Park, S., Park, S. Y., Kim, G., Park, S. M., Cho, J.-W., Kim, D. H., Park, Y. M., Koh, Y. W., Kim, H. R., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/641316 · Cited by 6
Self-citationTargeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance
Cheng, X., Wang, P., Lyu, H., Lee, Y., Yoon, J., & Dong, H. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.132 · Cited by 16
Fei, J., Cai, C., Wu, W., Shen, H., Han, Y., & Zeng, S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102728 · Cited by 6
Wang, S., Liang, Y., Zhang, J., Wang, W., Hong, Y., Sun, M., Shu, J., & Chen, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961634 · Cited by 6
“VEGF is an important angiogenic factor that is not only important for angiogenesis of tumors, but also, through binding to VEGFR on immune cells, upregulates the expression of immune checkpoints (PD-1, CTLA-4, TIM-3, LAG-3), thereby leading to the impairment of the function of effector T cells and T cells exhaustion (…”
BackgroundLiu, L., Zhang, X., Zhou, L., Yang, T., Qiao, Y., & Jiang, X. (2021) · Medicine · doi:10.1097/md.0000000000027138 · Cited by 6
Immunotherapy for Colorectal Cancer
Mukherji, R., Weinberg, B. A., & Pedersen, K. S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.010 · Cited by 4
Park, B., Heo, S., Lee, Y. J., Seo, M.-K., Hong, J., Shin, E., Jung, I., & Kim, S. (2022) · iScience · doi:10.1016/j.isci.2022.104467 · Cited by 5
“The VEGF-A/VEGFR2 interaction can enhance the expression of TOX, a master regulator of T cell exhaustion in CD8+ T cells (Kim et al., 2019; Voron et al., 2015).”
BackgroundSelf-citationCurrent status of chimeric antigen receptor T cell therapy and its exhaustion mechanism
Zhang, H., Gao, J., Zhang, Z., & Zhang, B. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2560798 · Cited by 3
Jafarlou, M., Jafarlou, V., Nouri, S., Alizadeh, N., Tabrizi, Z. A., Iravani, M., Ghorbaninezhad, F., Shakiba, D., & Baradaran, B. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04385-1 · Cited by 3
Kong, L.-Z., Zheng, Y., & Li, K. (2023) · Immunotherapy · doi:10.2217/imt-2023-0235 · Cited by 3
Saeed, A., Colby, S., Oberstein, P. E., Duda, D. G., Park, R., Agarwal, R., Figueroa-Moseley, C., Vaidya, R., Unger, J. M., Guthrie, K. A., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2485020 · Cited by 3
“More importantly, combined VEGF and PD-1/L1 inhibition has shown synergistic efficacy in animal models, which were associated with the reversal of T cell exhaustion [18,19].”
Zhong, M., Wang, Y., Nisar, M. F., Gao, J., & Bian, C. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.13047 · Cited by 4
Dammeijer, F. F., Dumoulin, D. W., & Aerts, J. G. J. V. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.001 · Cited by 3
Matsumoto, K., Naito, Y., Shiroyama, T., Tamiya, M., Nishino, K., Tamiya, A., Okishio, K., Kinehara, Y., Kuge, T., Mori, M., et al. (2026) · Cancer Science · doi:10.1111/cas.70336 · Cited by 2
Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances
Shi, J., Wang, J., 罗红梅, Zhao, Q., Yao, Z., Wu, G., Li, Z., Wang, H., Chen, G. D., & Wu, D. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128659 · Cited by 2
Fang, X., Wang, F., Li, H., Xiao, P., Wang, M., Wu, N., Yao, X., & Shi, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218824 · Cited by 2
Xiong, Y., Xiong, W., Wang, Y., He, C., Zhan, Y., Pan, L., Luo, L., & Song, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-03712-2 · Cited by 2
“Further analysis revealed that high ISs scores were positively correlated with tumor mutation burden (TMB) and could effectively predict responses to immune checkpoint inhibitors (e.g., PD1 and CTLA4) 16–20 .”
Immunogenicity of neoantigens: From CAR-T cell to various vaccines
Davodabadi, F., Arabpour, J., Goleij, P., Mohammadi, E., Taheri, M., Sethi, G., Dua, K., & Sarhadi, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125924 · Cited by 1
Franzese, O., Palermo, B., Lacal, P. M., & Graziani, G. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116380 · Cited by 2
PD-L1, treatment intensity, and outcomes in squamous NSCLC
Huang, S., Yang, G., & Tang, P. M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00143-1 · Cited by 1
Cancer Cell-Intrinsic Programs That Shape Tumor Immune Ecosystems
Wang, L., Guo, Y., Ma, L., & Miao, K. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.33 · Cited by 1
Cheng, J., Lu, J., Gao, Z., Xiao, Y., Chen, P. J., Zhou, M., Huang, D. J. Y., Zhao, Z., Zhang, X., Zhao, Y., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013637 · Cited by 1
“Then we tested the binding of endogenous proteins using lysates of exhausted CD8 + T cells and CLEC2B + CD4 + T cells sorted from patients with MSS CRC. Consistently, CLEC2B is immunoprecipitated down by anti-KLRB1 (figure 5e).”
InfluentialFeng, Y., Wang, Y., Li, X., Wang, Y., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810065 · Cited by 3
“It also impairs DC maturation and induces expression of checkpoints on T cells via the transcription factor thymocyte selection-associated high mobility group box (TOX), driving T cell exhaustion (252).”
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
“Mechanistically, VEGF-A inhibitors may potentiate the efficacy of PD-1/PD-L1 antibodies by normalizing the tumor vasculature, increasing T-cell infiltration, and reducing the activity of immunosuppressive cell populations (Kim et al., 2019).”
Go, E., Yang, H., Lee, S. J., Yang, H. G., Shin, J. A., Lee, W. S., Lim, H. S., Chon, H. J., & Kim, C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2259212 · Cited by 1
“18,22 Moreover, activated T cells not only express VEGFR2 but also VEGFR1, and the engagement of VEGFR 24,25 in these cells can directly modulate T cell functions, such as T cell trafficking or IL-10 production.”
BackgroundSelf-citationVizioli, G., Nicoletti, A., Daniela, F., Funaro, B., Verme, L. Z. D., Ponziani, F. R., Zocco, M. A., Gasbarrini, A., & Gabrielli, M. (2025) · Applied Sciences · doi:10.3390/app15052279 · Cited by 3
Integrating Context of Tumor Biology and Vaccine Design to Shape Multidimensional Immunotherapies
Wang, N. S., & Maine, C. J. (2020) · Future Drug Discovery · doi:10.4155/fdd-2019-0031 · Cited by 1
Investigating epigenetic therapies and combinations for the treatment of cancers
O’Brien, S. W. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20620610 · Cited by 1
Arcanjo, A. F., Logullo, J., Leite, P. E. C., Menezes, C. C. B., Freire-de-Lima, C. G., Granjeiro, J. M., Barroso, S. P. C., Conceição‐Silva, F., Savino, W., & Morrot, A. (2020) · Research Square · doi:10.21203/rs.3.rs-118495/v1
The immunoregulation of autoimmune diabetes
Hu, H. (2021) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/3sz5-xf29
(2021) · British Journal of Cancer Research · doi:10.31488/bjcr.160
Metadata
- Authors
- Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., Kwon, M., Kim, J. H., Lee, A. J., Nam, S. K., Bae, S.-J., Lee, S. B., Shin, S. J., Park, S. H., Ahn, J. B., Jung, I., Lee, K. Y., Park, S.-H., Kim, H., Min, B. S., & Shin, E.-C.
- Affiliations
- Korea Advanced Institute of Science and Technology (KR)
- Yonsei University (KR)
- Corresponding author
- Kim, Chang Gon
- Jang, Mi
- Kim, Hoguen
- Min, Byung Soh
- Shin, Eui-Cheol
- ORCID
- Kim, Chang Gon
- Jang, Mi
- Kim, Youngun
- Leem, Galam
- Kim, Kyung Hwan
- Lee, Hoyoung
- Kim, Tae-Shin
- Choi, Seong Jin
- Kim, Hyung-Don
- Han, Ji Won
- Kwon, Minsuk
- Kim, Jong Hoon
- Lee, Andrew J.
- Nam, Su Kyung
- Bae, Seok-Joo
- Lee, Sat Byol
- Shin, Sang Joon
- Park, Sung Ho
- Ahn, Joong Bae
- Jung, Inkyung
- Lee, Kang Young
- Park, Su-Hyung
- Kim, Hoguen
- Min, Byung Soh
- Shin, Eui-Cheol
- Venue
- Science Immunology
- Published
- 2019-11
- Volume
- 4
- Issue
- 41
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2989029645
- Cited by
- 245
- References
- 67
- Citations by year
- 2026: 29 · 2025: 25 · 2024: 45 · 2023: 32 · 2022: 46 · 2021: 43 · 2020: 24 · 2019: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Ministry of Science and ICT (NRF-2018M3A9D3079498)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- VEGF-A, TOX transcription factor, T cell exhaustion, anti-PD-1 resistance, microsatellite stable colorectal cancer, immune checkpoint blockade, tumor-infiltrating T cells, antitumor immunity
- MeSH terms
- Animals, High Mobility Group Proteins, Humans, Mice, Inbred C57BL, T-Lymphocytes, Colorectal Neoplasms, Homeodomain Proteins, Microsatellite Repeats, Caco-2 Cells, Vascular Endothelial Growth Factor A, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.